Skip to main content
LEQVIO® (inclisiran) injection 284 mg/1.5 mL

After a recent coronary event,* non-adherence could be getting in the way of your patients reaching and remaining at LDL-C target1-4

49% higher rate of cardiovascular events in patients who failed to reach LDL-C goal5†

The effect of LEQVIO® on cardiovascular morbidity and mortality has not been determined.

*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI) and/or coronary revascularization.6
Based on study (n=38,110,734) data that evaluated the annual cardiovascular event rates in a subset of guideline-defined high-risk patients of the Family Heart Database, which comprises diagnostic, procedure, lab, and prescription data from claims in the US from 2012 to 2021.5

Adherence Challenges


Many patients struggle to adhere to self-administered treatments

50%

of patients discontinue statins within 1 year1-4

 

>30%

of patients discontinue PCSK9 mAbs within 6 months7,8‡§

 

From an analysis of a large IQVIA open claims dataset of patients (N=72001) between January 2021 and December 2021.8
§In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAbs (N=13151) between January 1, 2016, and June 30, 2016, who were followed for a minimum of 6 months after their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.7

Sample Patient Profile


After a recent coronary event,* patients need immediate action to reduce LDL-C9

Michael, Not an actual patient

Michael, Patient With Coronary Artery Disease (CAD)

Recent Event: NSTEMI <12 months ago
Recent Procedure: PCI
LDL-C Level: 105 mg/dL
Additional CV Risk Factors: Hyperlipidemia, type 2 diabetes, hypertension
Current LDL-C Treatment: High-intensity statin

When statins aren’t enough, look to LEQVIO
 

Learn how to start your patients on LEQVIO

Discover resources for your practice and your patients.

Patient start form

Ready to add LEQVIO?

Start your patients on LEQVIO
Download
It’s possible to go from struggle to cholesterol (LDL-C) success with LEQVIO®

LEQVIO Patient Brochure

Inform patients about LEQVIO
Download
Es possible controlar exitosamente el cholesterol (C-LDL) con LEQVIO®

Spanish LEQVIO Patient Brochure

Inform patients about LEQVIO
Download

Dive into real-world adherence

See the data for the 12-month real-world adherence study

CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation myocardial infarction.
References: 1. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-461. 2. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410-1421. doi:10.1007/s11883-012-0291-7 3. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143-3421. 4. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291. 5. White paper: Prioritizing LDL-Cholesterol Control | Family Heart Foundation. Published September 30, 2023. Accessed July 9, 2024. https://familyheart.org/prioritizing-ldl-cholesterol-control 6. Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; July 10, 2023. 7. Hines DM, Rane P, Patel J, Harrison DF, Wade RL. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409-418. doi:10.2147/VHRM.S180496 8. Data on file. PCSK9 Discontinuation. Novartis Pharmaceuticals Corp; 2022. 9. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625